```
FILE 'HOME' ENTERED AT 14:59:58 ON 19 DEC 2003

=> file medline, uspatful, dgene, embase, biosis, wpids
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                            0.42       0.42

FILE 'MEDLINE' ENTERED AT 15:00:55 ON 19 DEC 2003

FILE 'USPATFULL' ENTERED AT 15:00:55 ON 19 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:00:55 ON 19 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 15:00:55 ON 19 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:00:55 ON 19 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'WPIDS' ENTERED AT 15:00:55 ON 19 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s myeloid cell and stimulation
L1         1269 MYELOID CELL AND STIMULATION

=> s HOIPS I or human oncogene induced secreted protein I
   3 FILES SEARCHED...
L2           21 HOIPS I OR HUMAN ONCOGENE INDUCED SECRETED PROTEIN I

=> d l2 ti abs ibib tot

L2   ANSWER 1 OF 21  USPATFULL on STN
TI     Method and system for providing real-time, in situ biomanufacturing
       process monitoring and control in response to IR spectroscopy
AB     A method and system for providing real-time, biomanufacturing process
       monitoring and control in response to infra-red (IR) spectroscopic
       fingerprinting of a biomolecule. IR spectroscopy is used to fingerprint
       an active biomolecule in situ in a biomanufacturing process. In one
       embodiment, Fourier Transform Infra-red spectroscopy (FTIR) is used to
       determine whether an active or aged biomolecule is present in stages of
       a biomanufacturing process. In one preferred example, the
       biomanufacturing process manufactures a biomaterial in bulk. The
       biomanufacturing process has four stages: bioproduction, recovery,
       purification, and bulk storage. FTIR spectroscopy is used to monitor the
       optimization of each process step by providing feedback controls, and to
       fingerprint in real-time, in situ whether active biomolecules are
       present in each stage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2002:280105  USPATFULL
TITLE:                    Method and system for providing real-time, in situ
                          biomanufacturing process monitoring and control in
                          response to IR spectroscopy
INVENTOR(S):              Naughton, Raymond A., West River, MD, UNITED STATES
                          Rohrer, Thomas R., Hagerstown, MD, UNITED STATES
                          Gentz, Reiner L., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S):       Human Genome Sciences, Inc. (U.S. corporation)

                               NUMBER         KIND    DATE
                          --------------- ------ --------
PATENT INFORMATION:       US 2002155541      A1   20021024
```

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                   August 1, 2003
 NEWS  5  AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS  6  AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS  7  AUG 18   Simultaneous left and right truncation added to PASCAL
 NEWS  8  AUG 18   FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                   Truncation
 NEWS  9  AUG 18   Simultaneous left and right truncation added to ANABSTR
 NEWS 10  SEP 22   DIPPR file reloaded
 NEWS 11  DEC 08   INPADOC: Legal Status data reloaded
 NEWS 12  SEP 29   DISSABS now available on STN
 NEWS 13  OCT 10   PCTFULL: Two new display fields added
 NEWS 14  OCT 21   BIOSIS file reloaded and enhanced
 NEWS 15  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS 16  NOV 24   MSDS-CCOHS file reloaded
 NEWS 17  DEC 08   CABA reloaded with left truncation
 NEWS 18  DEC 08   IMS file names changed
 NEWS 19  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 20  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 21  DEC 17   DGENE: Two new display fields added
 NEWS 22  DEC 18   BIOTECHNO no longer updated
 NEWS 23  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available

 NEWS EXPRESS  NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *
```

APPLICATION INFO.: US 2002-114469 A1 20020403 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2000-616894, filed on 14 Jul 2000, GRANTED, Pat. No. US 6395538

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157863P	19991006 (60)
	US 1999-151918P	19990901 (60)
	US 1999-144071P	19990716 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 21 USPATFULL on STN
TI **Human oncogene induced secreted protein I**
AB The present invention relates to a novel protein, the **Human Oncogene Induced Secreted Protein I** ("**HOIPS I**") protein. In particular, isolated nucleic acid molecules are provided encoding the human **HOIPS I** protein. **HOIPS I** polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:221411 USPATFULL
TITLE: **Human oncogene induced secreted protein I**
INVENTOR(S): Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119552	A1	20020829
APPLICATION INFO.:	US 2001-899917	A1	20010709 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-994962, filed on 19 Dec 1997, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33869P	19961220 (60)
	US 1997-37388P	19970207 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 21 USPATFULL on STN

TI Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy

AB A method and system for providing real-time, biomanufacturing process monitoring and control in response to infra-red (IR) spectroscopic fingerprinting of a biomolecule. IR spectroscopy is used to fingerprint an active biomolecule in situ in a biomanufacturing process. In one embodiment, Fourier Transform Infra-red spectroscopy (FTIR) is used to determine whether an active or aged biomolecule is present in stages of a biomanufacturing process. In one preferred example, the biomanufacturing process manufactures a biomaterial in bulk. The biomanufacturing process has four stages: bioproduction, recovery, purification, and bulk storage. FTIR spectroscopy is used to monitor the optimization of each process step by providing feedback controls, and to fingerprint in real-time, in situ whether active biomolecules are present in each stage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:122481 USPATFULL

TITLE: Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy

INVENTOR(S): Naughton, Raymond A., West River, MD, United States
Rohrer, Thomas R., Hagerstown, MD, United States
Gentz, Reiner L., Rockville, MD, United States

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6395538	B1	20020528	
APPLICATION INFO.:	US 2000-616894		20000714	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-157863P	19991006	(60)
	US 1999-144071P	19990716	(60)
	US 1999-151918P	19990901	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weber, Jon P.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 21 USPATFULL on STN

TI **Human oncogene induced secreted protein I**

AB The present invention relates to a novel protein, the **Human Oncogene Induced Secreted Protein I** ("**HOIPS I**") protein. In particular, isolated nucleic acid molecules are provided encoding the human **HOIPS I** protein. **HOIPS I** polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:147697 USPATFULL

TITLE: **Human oncogene induced secreted protein I**

INVENTOR(S): Olsen, Henrik S., Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284486	B1	20010904
APPLICATION INFO.:	US 1997-994962		19971219 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 69
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAW69220 Protein DGENE
AB This sequence is the **human oncogene induced secreted protein I** (**HOIPS I**) of the invention. **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAW69220 Protein DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
CROSS REFERENCES: N-PSDB: AAV44745
DESCRIPTION: **Human oncogene induced secreted protein I.**

L2 ANSWER 6 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44751 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (**HOIPS I**). **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44751 cDNA DGENE

TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag C02431.

L2 ANSWER 7 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44750 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (**HOIPS I**). **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44750 cDNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag T84854.

L2 ANSWER 8 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44749 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (**HOIPS I**). **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44749 cDNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag T92475.

L2 ANSWER 9 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44748 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (**HOIPS I**). **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44748 cDNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag T91708.

L2 ANSWER 10 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44758 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (**HOIPS I**) of the invention. **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44758 DNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I.**

L2 ANSWER 11 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44757 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (**HOIPS I**) of the invention. **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44757 DNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I.**

L2 ANSWER 12 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44756 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (**HOIPS I**) of the invention. **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44756 DNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I.**

L2 ANSWER 13 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44755 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (**HOIPS I**) of the invention. **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44755 DNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L2 ANSWER 14 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44754 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (**HOIPS I**) of the invention. **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44754 DNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L2 ANSWER 15 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44753 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human**

oncogene induced secreted protein
I (**HOIPS I**) of the invention. **HOIPS**
I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44753 DNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L2 ANSWER 16 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44752 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (**HOIPS I**) of the invention. **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44752 DNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L2 ANSWER 17 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44746 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (**HOIPS I**). **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for

detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44746 cDNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag.

L2 ANSWER 18 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44747 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (**HOIPS I**). **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44747 cDNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag AA340310.

L2 ANSWER 19 OF 21 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44745 cDNA DGENE
AB This sequence encodes the **human oncogene induced secreted protein I** (**HOIPS I**) of the invention. **HOIPS I** can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44745 cDNA DGENE
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as

leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
CROSS REFERENCES: P-PSDB: AAW69220
DESCRIPTION: **Human oncogene induced secreted protein I** coding sequence.

L2 ANSWER 20 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI **Human oncogene induced secreted protein I.**
AB The present invention relates to a novel protein, the **Human Oncogene Induced Secreted Protein I** ("**HOIPS I**") protein. In particular, isolated nucleic acid molecules are provided encoding the human **HOIPS I** protein. **HOIPS I** polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.
ACCESSION NUMBER: 2001:519304 BIOSIS
DOCUMENT NUMBER: PREV200100519304
TITLE: **Human oncogene induced secreted protein I.**
AUTHOR(S): Olsen, Henrik S. [Inventor]; Ruben, Steven M. [Inventor]
CORPORATE SOURCE: ASSIGNEE: Human Genome Sciences, Inc.
PATENT INFORMATION: US 6284486 September 04, 2001
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 4, 2001) Vol. 1250, No. 1. e-file. CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 7 Nov 2001
Last Updated on STN: 23 Feb 2002

L2 ANSWER 21 OF 21 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia.
AN 1998-377652 [32] WPIDS
AB WO 9828421 A UPAB: 19980812
An isolated nucleic acid molecule (I) is claimed comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to a sequence selected from:
(a) a NS encoding a polypeptide comprising amino acids from -20 to 142, -19 to 142, or 1 to 142 of the 162 amino acid (aa) sequence given in the specification (sequence representing a **Human Oncogene Induced Secreted Protein I** (**HOIPS I**) polypeptide);
(b) a NS encoding a polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825;
(c) a NS encoding a mature **HOIPS I** polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825; and
(d) a NS complementary to any of the NSs in (a)-(c).
Also claimed are:
(1) an isolated Nucleic Acid Molecule (NAM) comprising a PN which

hybridises under stringent hybridisation conditions (I) where the PN which hybridises does not hybridise under stringent hybridisation conditions to a PN having a NS consisting of only A residues or of only T residues;

(2) an isolated NAM comprising a PN which encodes an amino acid sequence of an epitope-bearing portion of a **HOIPS I** polypeptide having an amino acid sequence as in (a)-(c) above;

(3) an isolated NAM comprising a PN having a sequence at least 95% identical to a sequence selected from:

(a) a NS of a fragment of a 860 bp sequence given in the specification (encoding the **HOIPS I** polypeptide), where the fragment comprises at least 50 contiguous nucleotides of the 860 bp, provided that the NS is not one of the 514, 457, 413, 320, 264, and 249 sequences given in the specification; and

(b) a NS complementary to a NS as in (a);

(4) a method for making a recombinant vector comprising inserting (I) into a vector;

(5) a recombinant vector produced by a method as in (4);

(6) a method of making a recombinant host cell comprising introducing a recombinant vector as in (5) into a host cell;

(7) a recombinant host cell produced by a method as in (6);

(8) an isolated **HOIPS I** polypeptide having an amino acid sequence at least 95% identical to a sequence encoded by (I) or an epitope-bearing portion of the polypeptide;

(9) an isolated polypeptide comprising an epitope-bearing portion of the **HOIPS I** protein, where the portion is selected from a polypeptide comprising amino acid residues from -4 to 9, from 13 to 19, from 23 to 32, from 36 to 47, from 54 to 63, from 70 to 74, from 90 to 100, from 105 to 119 or from 125 to 132 of the 162 aa sequence;

(10) an isolated **HOIPS I** polypeptide where, except for 1 to 50 conservative amino acid substitutions, the polypeptide has a sequence selected from:

(a) amino acids from -20 to 142, 19 to 142, or 1 to 142 of the 162 aa sequence given in the specification;

(b) an amino acid sequence of the **HOIPS I** polypeptide having an amino acid sequence encoded by a cDNA contained in ATCC 97825;

(c) an amino acid sequence of a mature **HOIPS I** polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825; and

(d) an amino acid sequence of an epitope-bearing portion of any one of the polypeptides as in (a)-(c);

(11) an isolated nucleic acid encoding a polypeptide as in (10).

USE - The products can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis.

Dwg.0/3

ACCESSION NUMBER: 1998-377652 [32] WPIDS
DOC. NO. NON-CPI: N1998-295209
DOC. NO. CPI: C1998-114764
TITLE: New isolated human oncogene induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): OLSEN, H S; RUBEN, S M
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 81
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9828421	A1	19980702	(199832)*	EN	71

RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW

AU 9858027 A 19980717 (199848)
US 6284486 B1 20010904 (200154)
US 2002119552 A1 20020829 (200259)

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9828421	A1		WO 1997-US23547	19971219
AU 9858027	A		AU 1998-58027	19971219
US 6284486	B1	Provisional	US 1996-33869P	19961220
		Provisional	US 1997-37388P	19970207
			US 1997-994962	19971219
US 2002119552	A1	Provisional	US 1996-33869P	19961220
		Provisional	US 1997-37388P	19970207
		Div ex	US 1997-994962	19971219
			US 2001-899917	20010709

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9858027	A	Based on	WO 9828421

PRIORITY APPLN. INFO: US 1997-37388P 19970207; US 1996-33869P 19961220; US 1997-994962 19971219; US 2001-899917 20010709

=> d his

(FILE 'HOME' ENTERED AT 14:59:58 ON 19 DEC 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, BIOSIS, WPIDS' ENTERED AT 15:00:55 ON 19 DEC 2003
L1 1269 S MYELOID CELL AND STIMULATION
L2 21 S HOIPS I OR HUMAN ONCOGENE INDUCED SECRETED PROTEIN I

=> s l1 and l2
L3 0 L1 AND L2

=> s proliferation and l1
L4 799 PROLIFERATION AND L1

=> s l4 and l2
L5 0 L4 AND L2

=> d l4 ti abs ibib 1-5

L4 ANSWER 1 OF 799 MEDLINE on STN
TI B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro.
AB B lymphocyte stimulator (BLyS protein) is a member of the human TNF family of ligands. BLyS induces B-lymphocyte **proliferation** and Ig secretion in vitro and in vivo. These qualities suggest that it may be useful as a therapeutic in the treatment of immunodeficiencies characterized by low or absent serum immunoglobulin, such as common variable immunodeficiency (CVID). CVID is characterized by the inability to generate adequate serum Ig despite normal or slightly depressed peripheral B, T, and **myeloid cell** populations. We

tested the ability of BLyS to stimulate B lymphocytes obtained from CVID patients. Among five patients studied, 60% (three of five) produced normal quantities of IgM when cultured in the presence of BLyS. B-cell **proliferation** among patients was comparable, with 60% (three of five) responding to BLyS **stimulation**. These results suggest that BLyS induces proliferative and Ig-secretory responses in B lymphocytes isolated from some CVID patients and lend support to its potential use in therapy of this disorder.

ACCESSION NUMBER: 2003519115 IN-PROCESS
DOCUMENT NUMBER: 22959304 PubMed ID: 14597212
TITLE: B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro.
AUTHOR: Stewart Donn M; McAvoy Michael J; Hilbert David M; Nelson David L
CORPORATE SOURCE: Metabolism Branch, NCI, NIH, 10 Center Drive MSC 1374, Bethesda, MD 20892, USA.. dstew@helix.nih.gov
SOURCE: CLINICAL IMMUNOLOGY, (2003 Nov) 109 (2) 137-43. Journal code: 100883537. ISSN: 1521-6616.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20031105
Last Updated on STN: 20031119

L4 ANSWER 2 OF 799 MEDLINE on STN
TI Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and **myeloid cell proliferation** or death.
AB The heterodimeric interferon (IFN)-gamma receptor (IFN-gammaR) is formed of two chains. Here we show that the binding chain (IFN-gammaR1) was highly expressed on the membranes of T, B, and myeloid cells. Conversely, the transducing chain (IFN-gammaR2) was highly expressed on the surfaces of myeloid cells, moderately expressed on B cells, and poorly expressed on the surfaces of T cells. Differential cell membrane expression of IFN-gammaR2 determined the number of receptor complexes that transduced the IFN-gamma signal and resulted in a different response to IFN-gamma. After IFN-gamma **stimulation**, high IFN-gammaR2 membrane expression induced rapid activation of signal transducer and activator of transcription-1 (STAT-1) and high levels of interferon regulatory factor-1 (IRF-1), which then triggered the apoptotic program. By contrast, low cell membrane expression resulted in slow activation of STAT-1, lower levels of IRF-1, and induction of **proliferation**. Because the forced expression of IFN-gammaR2 on T cells switched their response to IFN-gamma from proliferative to apoptotic, we concluded that the surface expression of IFN-gammaR2 determines whether a cell stimulated by IFN-gamma undergoes **proliferation** or apoptosis.

ACCESSION NUMBER: 2001697308 MEDLINE
DOCUMENT NUMBER: 21602154 PubMed ID: 11739558
TITLE: Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and **myeloid cell proliferation** or death.
AUTHOR: Bernabei P; Coccia E M; Rigamonti L; Bosticardo M; Forni G; Pestka S; Krause C D; Battistini A; Novelli F
CORPORATE SOURCE: Department of Clinical and Biological Sciences, University of Turin, I-10043 Orbassano, Centro Ricerche di Medicina Sperimentale, S. Giovanni Battista Hospital, I-10126 Turin, Italy.
CONTRACT NUMBER: AI-36450 (NIAID)
CA-46465 (NCI)
SOURCE: JOURNAL OF LEUKOCYTE BIOLOGY, (2001 Dec) 70 (6) 950-60. Journal code: 8405628. ISSN: 0741-5400.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200112
ENTRY DATE: Entered STN: 20011218
Last Updated on STN: 20020123
Entered Medline: 20011221

L4 ANSWER 3 OF 799 MEDLINE on STN
TI Differentiation associated modulation of the cytokine and chemokine expression pattern in human **myeloid cell** lines.
AB Hematopoietic progenitor cell differentiation is associated with the expression of different sets of genes including those encoding membrane bound molecules and cytokines. While expression of the former has meticulously been linked to both lineage specificity and maturation stages and is routinely used in the diagnosis of human leukemias, the production of cytokines has not systematically been analyzed in this respect. Secretion of cyto- and chemokines by HPC has been discussed as a key element of autocrine regulation of cell differentiation and **proliferation** in normal and malignant hematopoietic cells. Hematopoietic cell lines and their in vitro generated mature progeny were used as a model to investigate the cytokine and chemokine expression pattern prior to and after induction of differentiation. We show that a variety of cytokines are produced by these cells either constitutively or upon **stimulation**. Low levels of TNF-alpha and IL-8 were widely expressed by immature and mature cells, while peak values of TNF-alpha were detected in promyelocytic NB4 cells, as reported previously. Induction of monocytic differentiation by various agents was associated with upregulation of IL-1 beta and IL-1ra expression, while a differentiation shift to the granulocytic lineage in the presence of retinoic acid (RA) led to a marked increase of macrophage chemoattractant protein-1 (MCP-1) producing cells. These data indicate that lineage determination as well as maturation of hematopoietic cells may not only be associated with expression of specific surface molecules but also with a distinct cytokine expression pattern. Further studies are necessary to show if this holds true for primary leukemic and normal hematopoietic cells.
ACCESSION NUMBER: 2001182046 MEDLINE
DOCUMENT NUMBER: 21104917 PubMed ID: 11166829
TITLE: Differentiation associated modulation of the cytokine and chemokine expression pattern in human **myeloid cell** lines.
AUTHOR: Behringer D; Schaufler J; Kresin V; Lubbert M; Lindemann A
CORPORATE SOURCE: Department of Haematology/Oncology, University of Freiburg, Hugstetterstr. 55, 79106 Freiburg, Germany.. behringer@mm11.ukl.uni-freiburg.de
SOURCE: LEUKEMIA RESEARCH, (2001 Feb) 25 (2) 141-9. Journal code: 7706787. ISSN: 0145-2126.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200103
ENTRY DATE: Entered STN: 20010404
Last Updated on STN: 20010404
Entered Medline: 20010329

L4 ANSWER 4 OF 799 MEDLINE on STN
TI Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell **proliferation** and can prevent the induction of non-responsiveness by CTLA4-Ig.
AB We investigate how lipopolysaccharide (LPS) could influence antigen-specific T-cell responses as well as tolerance induction. Using the recall antigen tetanus toxoid for primary in vitro T-cell **stimulation**, we observed that LPS synergized with peptides to

augment **proliferation**, particularly when used at low concentrations (as little as 100 pg/ml), and that interleukin-12 (IL-12) was partially required for this synergistic effect. Because of the clear enhancement of in vitro peptide-specific responses we then tested whether LPS could influence antigen-specific tolerance driven by coincubation of antigen (tetanus toxoid; TT or immunodominant peptides) with human CTLA-4Ig fusion protein. As expected, CTLA-4Ig treatment inhibited responses to peptides. LPS (100 pg/ml) induced a partial recovery of primary in vitro **proliferation** under these conditions and the presence of LPS during the primary **stimulation** prevented the induction of tolerance normally observed on re-**stimulation** with the same antigen alone. Contrary to the synergistic effects on peptide **proliferation** this action was not caused by release of IL-12. In addition, the neutralization of tumour necrosis factor-alpha (TNF-alpha) during the primary **stimulation** did not inhibit **proliferation** on re-**stimulation** with peptide. LPS could therefore exert dramatic effects on antigen-specific **proliferation** and CTLA-4Ig-induced non-responsiveness in human T cells, although via distinct mechanisms. These results reinforce the evidence that LPS influences T-cell function, most likely as a consequence of **myeloid cell** activation.

ACCESSION NUMBER: 2001134833 MEDLINE
DOCUMENT NUMBER: 21100916 PubMed ID: 11168632
TITLE: Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell **proliferation** and can prevent the induction of non-responsiveness by CTLA4-Ig.
AUTHOR: Goodier M R; Londei M
CORPORATE SOURCE: Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, London W6 8LH, UK.
SOURCE: IMMUNOLOGY, (2001 Jan) 102 (1) 15-23.
Journal code: 0374672. ISSN: 0019-2805.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200103
ENTRY DATE: Entered STN: 20010404
Last Updated on STN: 20010404
Entered Medline: 20010301

L4 ANSWER 5 OF 799 MEDLINE on STN
TI 20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor.
AB 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) plays a major role in the **stimulation** of bone growth, mineralization, and intestinal calcium and phosphate absorption; it also acts as a general inhibitor of cellular **proliferation**. Several new, clinically relevant compounds dissociate antiproliferative and calcemic activities of 1,25(OH)2D3, but the molecular basis for this has not been clearly elucidated. Here, we tested whether the potency of one class of compounds, 20-epi analogues, to induce **myeloid cell** differentiation, is because of direct molecular effects on vitamin D receptor (VDR). We report that two 20-epi analogues, MC1627 and MC1288, induced differentiation and transcription of p21(Waf1,Cip1), a key VDR target gene involved in growth inhibition, at a concentration 100-fold lower than that of 1,25(OH)2D3. We compared this sensitivity to analogue effects on VDR interacting proteins: RXR, GRIP-1, and DRIP205, a subunit of the DRIP coactivator complex. Compared with the interaction of VDR with RXR or GRIP-1, the differentiation dose-response most closely correlated to the ligand-dependent recruitment of the DRIP coactivator complex to VDR and to the ability of the receptor to activate transcription in a cell-free system. These results provide compelling links between the efficiency of

the 20-epi analogue in inducing VDR/DRIP interactions, transactivation in vitro, and its enhanced ability to induce cellular differentiation.

ACCESSION NUMBER: 1999287876 MEDLINE
DOCUMENT NUMBER: 99287876 PubMed ID: 10358028
TITLE: 20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor.
AUTHOR: Yang W; Freedman L P
CORPORATE SOURCE: Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
CONTRACT NUMBER: CA08748 (NCI)
DK07313 (NIDDK)
DK45460 (NIDDK)
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 Jun 11) 274 (24) 16838-45.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199907
ENTRY DATE: Entered STN: 19990715
Last Updated on STN: 19990715
Entered Medline: 19990706